Stimulant Medication Use in Congenital Heart Disease

Children with congenital heart disease (CHD) are at risk for neurodevelopmental problems including attention-deficit hyperactivity disorder.[Vetter: 2008] [Bass: 2004] [Kirshbom: 2005] While there have been reports of sudden cardiac death (SCD) in children without CHD using psychostimulant medications, this risk is no greater than that for SCD in the general population.[Perrin: 2008] There are no clinical studies suggesting that children with most forms of CHD are at risk for SCD while taking stimulant medications. According to the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing, it is reasonable to consider treatment of ADHD in patients with corrected or uncorrected CHD that is stable unless the patient's pediatric cardiologist has specific concerns. The following conditions are associated with an increased risk of SCD and while they do not contraindicate the use of stimulants, these medications must be used with caution and close monitoring:[Keane: 2006]
  • Heart condition associated with SCD (prolonged QT syndrome, short-QT syndrome, hypertrophic cardiomyopathy, arrhythmogenic right ventricular dysplasia, Brugada syndome, coronary anomaly, Wolff-Parkinson-White syndrome, Marfan syndrome)
  • History of an arrhythmia requiring cardiopulmonary resuscitation, direct current cardioversion or defibrillation, or overdrive pacing
  • Previous aborted SCD
  • Other clinically significant arrhythmia not treated or controlled
  • QTc on ECG >0.46 seconds
  • Heart rate or blood pressure >2 SD above means for age
If any of the above conditions or arrhythmias are diagnosed during treatment, consideration should be given to discontinuation of the stimulant medication until further testing and treatment can be achieved. If arrhythmias are treated and controlled, on approval of a pediatric cardiologist, the patient may be restarted on medication.

Authors & Reviewers

Initial publication: July 2010; last update/revision: November 2014
Current Authors and Reviewers:
Author: Catherine Jolma, MD

Page Bibliography

Bass JL, Corwin M, Gozal D, Moore C, Nishida H, Parker S, Schonwald A, Wilker RE, Stehle S, Kinane TB.
The effect of chronic or intermittent hypoxia on cognition in childhood: a review of the evidence.
Pediatrics. 2004;114(3):805-16. PubMed abstract

Keane, JF, Fyler DC, and JE Lock .
Nadas' Pediatric Cardiology.
Second ed. Saunders; 2006. 1416023909

Kirshbom PM, Flynn TB, Clancy RR, Ittenbach RF, Hartman DM, Paridon SM, Wernovsky G, Spray TL, Gaynor JW.
Late neurodevelopmental outcome after repair of total anomalous pulmonary venous connection.
J Thorac Cardiovasc Surg. 2005;129(5):1091-7. PubMed abstract

Perrin JM, Friedman RA, Knilans TK.
Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
Pediatrics. 2008;122(2):451-3. PubMed abstract / Full Text

Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL.
Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.
Circulation. 2008;117(18):2407-23. PubMed abstract / Full Text